LDS/Medical Tests/Hereditary Hemochromatosis (HFE) Mutation Assay

Hereditary Hemochromatosis (HFE) Mutation Assay

Heriditary hemochromatosis (HH) is an inherited disorder that increases the amount of iron that is absorbed by the body from the digestive tract. This increase in iron is systemic (affects multiple body systems) affecting mostly the liver, pancreas, heart, and endocrine systems. Although approximately 80% of the cases of hemochromatosis are from Northern Europe, the disorder affects approximately 1 in every 125 to 333 individuals in the U.S. If this disorder is untreated it is associated with significant morbidity or premature death. Normal individuals absorb approximately 2 mg of iron per day while individuals with hemochromatosis absorb twice as much. This increased storage of iron in the body is due to the inability of the body to dispose of the excess iron. The increase in iron in the liver can lead to cirrhosis, which can progress to liver cancer; increases in the pancreas can lead to diabetes mellitus. The increased amount of iron that is accumulated in the body can cause cardiomyopathy (enlarged, thickened, or stiff heart muscle), arthritis, and minor changes (bronzing) of the skin can also occur. Even though hemochromatosis is one of the most common autosomal recessive disorders, very few individuals suffer from any symptoms.

HH is an autosomal recessive disease caused by a point mutation in the hemochromatosis (HFE) gene also known as transferrin-receptor binding protein. HFE is located close to the HLA-A locus on chromosome 6. This gene mutation results from a single point mutation at amino acid 282 of the HH protein that converts a cysteine to tyrosine (C282Y). The C282Y mutation is the most common, and because hemochromatosis is an autosomal recessive disease, this mutation occurs mainly in the heterozygous form affecting more than 15% of the Caucasian population. A very small percentage (<0.5%) of the population is homozygous for this mutation; however, 83% develop iron overload disease. Heterozygotes have higher transferrin saturation and ferritin values than wild-type genotypes (normal genotypes); however, these individuals rarely develop iron overload disease. A second HFE mutation, H63D, occurs in a smaller percentage of patients than C282Y and is mostly asymptomatic. Screening or diagnostic testing should be performed for both mutations C282Y and H63D. Because the C282Y mutation is very uncommon in Asian and African population, this test is less useful in people from these ethnic backgrounds. 

HFE Genotype % Prevalence in Population % Developing Disease
C282Y homozygous 0.5% 82.0%
Compound heterozygous 2.0% 3.5%
H63D homozygous 1.6% 1.2%
C282Y heterozygous 12–15% 1.5%
H63D heterozygous 24.5% 1.5%

 

  • Diagnostic confirmation of hemochromatosis in an individual with biochemical or clinical findings of iron overload
  • Screening and evaluation of suspected hemochromatosis and their relatives
  • Carrier testing for the reproductive partner of an individual with hemochromatosis
  • Differential diagnosis of liver disease with increased iron overload
  • Screening family members of individuals with a C282Y/C282Y or C282Y/H63D genotype
  • Prevention and treatment of Cirrhosis

Present in:

  • Hemochromatosis
  • Iron overload disease
  • Liver disease
  • Liver cirrhosis
  • Liver cancer
  • Diabetes mellitus
  • Cardiomyopathy

Decreased in:

  • Normal wild types
  • Some types of anemia (iron deficiency anemia)

Note: the diagnosis of hemochromatosis is based on a combination of clinical findings, laboratory results, and other diagnostic criteria. The best initial test for hemochromatosis is a transferrin saturation test. If the transferrin saturation is >45%, it should be repeated along with a serum ferritin test and iron levels. In adults, when both the serum transferrin saturation and ferritin are elevated, the hemochromatosis gene mutation test should be performed.

Homozygosity for the C282Y mutation in individuals with clinical and biochemical evidence of iron overload provides confirmation of a diagnosis of HH. Asymptomatic individuals who are homozygous for the C282Y mutation are at high risk for iron overload, yet only a minority will develop clinicalsymptoms of HH.

Detection of compound heterozygosity for C282Y/H63D in individuals with clinical and biochemical evidence of iron overload provides diagnostic confirmation of HH. Asymptomatic C282Y/H63D compound heterozygotes are at moderate risk for iron overload, and less than 2 percent will develop clinical symptoms.

No mutation detected (Normal wild type for hemochromatosis)
 

 

 

Genetic testing by sequencing, Amplification Refractory Mutation System (ARMS), Real-Time PCR, C-Reactive Protein (elevated).

Whole blood EDTA (Lavender), ACD (Yellow) or Heparin (Green). 

Stability

  • Ambient: 3-5 days
  • Refrigerated: 5-7 days
  • Frozen: 30 days
CBC (usually normal), C-reactive protein (usually high), Blood sedimentation rate (elevated), Serum ferritin (elevated), Serum iron (mostly decreased), Transferrin saturation (decreased), Total Iron Binding Compound (TIBC) (elevated), Liver Profile (usually abnormal), Liver biopsy (to estimate the liver damage), Transferrin receptor.

1- 2 weeks. 

Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login